Reason | Number | Percent |
---|---|---|
Lack of efficacy | ||
Alone | 199 | 35.0 |
In combination with lack of tolerability | 50 | 8.8 |
Total | 249 | 43.8 |
Lack of tolerability | ||
Alone | 319 | 56.2 |
In combination with lack of efficacy | 50 | 8.8 |
Total | 369 | 65.0 |
Lack of tolerability, analytically (n = 369)* | ||
Weight gain | 149 | 40.4 |
Extrapyramidal symptoms | 111 | 30.1 |
Lack of tolerance | 42 | 11.4 |
Hyperprolactinaemia | 39 | 10.6 |
Hyperlipidaemia and/or glucose increase | 24 | 6.5 |
Stress/insomnia/anxiety/akathisia | 16 | 4.3 |
Sleepiness/drowsiness | 12 | 3.2 |
Gynecological dysfunctions | 6 | 1.6 |
Sexual disorders | 6 | 1.6 |
Other adverse events | 10 | 2.7 |